CVS Health (NYSE:CVS) Updates FY 2025 Earnings Guidance

CVS Health (NYSE:CVS) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 5.750-6.000 for the period, compared to the consensus earnings per share estimate of 5.900. The company issued revenue guidance of -.

CVS Health Stock Performance

Shares of NYSE CVS opened at $63.79 on Tuesday. The business’s 50-day simple moving average is $63.62 and its 200-day simple moving average is $58.05. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.60 and a current ratio of 0.81. CVS Health has a 52 week low of $43.56 and a 52 week high of $74.85. The firm has a market cap of $80.43 billion, a price-to-earnings ratio of 17.43, a P/E/G ratio of 0.98 and a beta of 0.57.

CVS Health (NYSE:CVS) last released its earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share for the quarter, topping analysts’ consensus estimates of $0.89 by $0.30. CVS Health had a net margin of 1.24% and a return on equity of 9.11%. As a group, equities research analysts expect that CVS Health will post 5.89 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, May 1st. Investors of record on Tuesday, April 22nd will be paid a $0.665 dividend. This represents a $2.66 annualized dividend and a dividend yield of 4.17%. The ex-dividend date is Tuesday, April 22nd. CVS Health’s payout ratio is presently 72.68%.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on CVS. UBS Group cut their target price on CVS Health from $62.00 to $59.00 and set a “neutral” rating for the company in a research note on Tuesday, February 11th. Barclays increased their price target on shares of CVS Health from $71.00 to $73.00 and gave the stock an “overweight” rating in a research report on Thursday, February 13th. Argus set a $77.00 price objective on CVS Health in a report on Tuesday, February 18th. Leerink Partners raised CVS Health from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $55.00 to $75.00 in a report on Thursday, February 13th. Finally, Piper Sandler boosted their price target on CVS Health from $72.00 to $74.00 and gave the company an “overweight” rating in a research note on Friday, March 21st. Four analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $70.39.

Insider Activity at CVS Health

In other news, SVP James David Clark sold 7,513 shares of CVS Health stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total value of $498,487.55. Following the completion of the sale, the senior vice president now directly owns 8,394 shares of the company’s stock, valued at approximately $556,941.90. This trade represents a 47.23 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Michael F. Mahoney purchased 30,000 shares of the business’s stock in a transaction dated Tuesday, February 18th. The shares were purchased at an average cost of $66.70 per share, for a total transaction of $2,001,000.00. Following the purchase, the director now directly owns 39,356 shares of the company’s stock, valued at $2,625,045.20. This trade represents a 320.65 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.24% of the stock is currently owned by company insiders.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.